Group 1 - Morgan Stanley has raised its revenue forecasts for JD Health for 2025, 2026, and 2027 by 1.7%, 2%, and 2.3% respectively, considering the continued online penetration trend in drug sales during the first half of the year [1] - Net profit forecasts have been increased by 14.7%, 14.5%, and 13% respectively, attributed to the improvement in gross margin from product mix transformation and cost control [1] - The target price for JD Health has been raised from HKD 46 to HKD 52.5, maintaining a rating of "in line with the market" [1]